Deep-dive briefing

Thu · 8 Oct 2026

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.

Phase 2 Evidence and Impact Analysis

Each article is assessed independently across five dimensions, with key quantitative results, validation status, limitations, equity implications, and evidence maturity confirmation or revision noted.

Article 1 — Meaden et al.: Reducing socio-economic inequalities in bowel cancer screening (PMID 42842613)

Triage Score: 8 | Flag: 🟡 UNDERSERVED_POPULATION

Dimension	Score	Rationale
Scientific Novelty	3	Synthesizes known interventions; no new methodology or discovery
Clinical Relevance	5	Important for policy and programme design; not directly changing clinical management
Population Reach	7	Bowel cancer is common; socioeconomic gaps in screening affect large populations in UK and globally
Implementation Speed	6	Systematic review findings can inform programme updates relatively quickly
Evidence Strength	6	Systematic review design is high-level but conclusions are qualified and call for further research

Key quantitative result: Not reported in abstract; conclusions are qualitative
External validation: Aggregate synthesis; no new primary validation
Main limitation: Heterogeneity of interventions; mechanisms of effectiveness unclear; abstract-only access
Equity implications: Directly addresses deprived communities; findings most relevant to high-income countries with organised screening programmes; lower-income countries without such infrastructure remain underserved
Evidence Maturity Revision: Validated → Validated (confirmed; synthesis of existing evidence, but no new mechanistic insight)

Phase 2 Composite Score: (5×0.30) + (7×0.25) + (3×0.20) + (6×0.15) + (6×0.10) = 5.50

Article 2 — Lee et al.: Clinical Practice Guidelines for PE/BALF-Based ctDNA Testing in Lung Cancer (PMID 42844226)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	Formalises emerging practice; guidelines lag behind discovery but fill important gap
Clinical Relevance	6	Directly applicable to lung cancer molecular testing decisions
Population Reach	7	Lung cancer is the most common cause of cancer death globally
Implementation Speed	5	Guidelines require institutional validation and uptake; BALF evidence particularly thin
Evidence Strength	4	Consensus-based, not data-driven; classification_confidence = medium; abstract only

Key quantitative result: Not reported; consensus-based guidance
External validation: No primary validation; consensus process methodology unclear from abstract
Main limitation: Evidence base specifically for BALF is acknowledged as insufficient; matrix-specific data gaps
Equity implications: Accessible primarily to high-resource oncology centres with molecular testing infrastructure; may widen detection gap in LMIC settings
Evidence Maturity Revision: Exploratory → Exploratory (confirmed; consensus guidance without new primary evidence)

Phase 2 Composite Score: (6×0.30) + (7×0.25) + (5×0.20) + (5×0.15) + (4×0.10) = 5.80

Article 3 — Vidotto et al.: Robotic Bariatric Surgery in BMI >50 kg/m² (PMID 42844217)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	3	Robotic bariatrics is established; this extends evidence to a higher BMI tier but is incremental
Clinical Relevance	5	Useful for surgical planning in super-obese patients; n=47 studies limits confidence
Population Reach	6	Super-obesity (BMI >50) is a growing and underserved surgical population
Implementation Speed	5	Robotic platforms are available in many centres; adoption depends on training and cost
Evidence Strength	5	Systematic review but very small constituent study count (47 patients); abstract only

Key quantitative result: Not specified beyond feasibility/safety conclusions
External validation: Aggregate; no independent prospective validation
Main limitation: Extremely small aggregated sample; likely heterogeneous procedures and outcomes
Equity implications: Robotic platforms concentrated in high-income/academic centres; patients in low-resource settings excluded
Evidence Maturity Revision: Validated → Exploratory (downgraded; n=47 is too small for confident conclusions)

Phase 2 Composite Score: (5×0.30) + (6×0.25) + (3×0.20) + (5×0.15) + (5×0.10) = 4.85

Article 4 — Quraishi & El Ouali: Subcutaneous Infliximab in IBD (PMID 42844215)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	4	SC infliximab (CT-P13 SC) already approved; review synthesises PK rationale and future trajectory
Clinical Relevance	6	SC formulation has real patient-convenience and pharmacokinetic advantages; could shift standard of care
Population Reach	6	IBD affects ~10 million people globally; infliximab is widely used
Implementation Speed	7	SC infliximab already available in many markets; 5-year adoption horizon cited in paper
Evidence Strength	4	Narrative/expert review; classification_confidence = medium; abstract only

Key quantitative result: Not reported; expert projection of 5-year adoption
External validation: Not applicable (review/opinion)
Main limitation: No new primary data; adoption timeline is speculative
Equity implications: SC route could democratise outpatient access but biosimilar pricing and cold-chain logistics remain barriers in LMICs
Evidence Maturity Revision: Exploratory → Exploratory (confirmed)

Phase 2 Composite Score: (6×0.30) + (6×0.25) + (4×0.20) + (7×0.15) + (4×0.10) = 5.65

Article 5 — Yamada et al.: Lipoprotein(a) and Polyvascular Disease Burden (PMID 42844202)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	Extends Lp(a) literature to polyvascular burden; incremental but clinically meaningful as Lp(a)-lowering drugs enter trials
Clinical Relevance	6	Lp(a) is attracting clinical attention with emerging therapeutic options (e.g., pelacarsen, olpasiran)
Population Reach	7	Cardiovascular disease is globally prevalent; elevated Lp(a) affects ~20% of the population
Implementation Speed	5	Lp(a) testing is not universally performed; therapeutic options still investigational
Evidence Strength	5	Prospective cohort, n=1799; observational, no causal inference; abstract only

Key quantitative result: Independent association of higher Lp(a) with increased polyvascular disease burden; specific ORs not reported in abstract
External validation: Consistent with prior Lp(a) literature; no replication in this paper
Main limitation: Observational; confounding possible; Japanese single-centre cohort may limit generalisability
Equity implications: Lp(a) testing and emerging therapies are currently accessible mainly in affluent healthcare systems; populations with highest cardiovascular burden (sub-Saharan Africa) may benefit least near-term
Evidence Maturity Revision: Validated → Validated (confirmed; adds to a well-established evidence base)

Phase 2 Composite Score: (6×0.30) + (7×0.25) + (5×0.20) + (5×0.15) + (5×0.10) = 5.80

Article 6 — Karlamangla et al.: Cardiovascular Risk Factor Changes after Great Recession (MESA) (PMID 42843884)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	Longitudinal follow-up of GR effects over 8–10 years is novel; demonstrates persistence not previously documented
Clinical Relevance	4	Primarily policy-relevant; clinical actionability is indirect
Population Reach	7	Multi-ethnic US cohort; implications for populations experiencing economic adversity globally
Implementation Speed	3	Primarily informing long-term public health policy; slow to translate
Evidence Strength	6	Prospective cohort (n=3101), fixed-effects analysis is methodologically appropriate; abstract only

Key quantitative result: Post-GR BP, glucose, and CRP elevations persisted and grew in magnitude over 8–10 years; BMI and LDL-C showed reductions
External validation: Supported by prior recession-CVD literature; not yet externally replicated for the long-term persistence finding
Main limitation: US-specific; mechanisms not elucidated; observational design
Equity implications: Highly equity-relevant; disproportionate effects on minority and low-income populations; BMI/LDL improvements may reflect food insecurity rather than healthy behaviour
Evidence Maturity Revision: Validated → Validated (confirmed)

Phase 2 Composite Score: (4×0.30) + (7×0.25) + (5×0.20) + (3×0.15) + (6×0.10) = 4.90

Article 7 — Otile et al.: AI in Surgical Healthcare — Systematic Review Protocol (PMID 42843882)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	2	Protocol only; no findings yet
Clinical Relevance	3	Downstream potential; no results to evaluate
Population Reach	5	Surgical AI is broadly applicable if review yields actionable results
Implementation Speed	2	Protocol stage; review completion and translation are years away
Evidence Strength	3	Protocol publication; no data

Key quantitative result: None (protocol)
Main limitation: No findings; protocol registered but outcome uncertain
Equity implications: African authorship suggests interest in LMIC contexts, which is welcome, but review scope unclear
Evidence Maturity Revision: Validated → Exploratory (downgraded; this is a protocol, not a completed review)

Phase 2 Composite Score: (3×0.30) + (5×0.25) + (2×0.20) + (2×0.15) + (3×0.10) = 3.05

Article 8 — Forsberg et al.: Colonoscopy Quality — Nurse Endoscopists vs. Physicians in Sweden (PMID 42843632)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	4	Nurse endoscopist competency is increasingly studied; Swedish nationwide data adds scale
Clinical Relevance	7	Directly applicable to screening workforce planning; addresses a real capacity bottleneck
Population Reach	7	Colorectal cancer screening programmes serve millions; workforce solution has broad applicability
Implementation Speed	7	Policy-level change already occurring in some countries; findings could accelerate adoption
Evidence Strength	5	Observational/registry-based; no randomisation; Swedish national programme lends external validity; abstract only

Key quantitative result: Nurse endoscopists demonstrated high-quality colonoscopy performance metrics (specific figures not available in abstract)
External validation: Consistent with growing international literature on nurse endoscopists
Main limitation: No randomisation; possible selection bias in case complexity; Sweden-specific workforce context
Equity implications: Expanding the endoscopist workforce could reduce access disparities; particularly relevant where physician shortages limit screening uptake
Evidence Maturity Revision: Exploratory → Validated (upgraded; real-world national programme data supports this as validated)

Phase 2 Composite Score: (7×0.30) + (7×0.25) + (4×0.20) + (7×0.15) + (5×0.10) = 6.25

Article 9 — Schaiter et al.: Multi-omic Muscle Processes in Pompe Disease (PMID 42843417)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	6	Multi-omic approach across infantile and late-onset Pompe in same study is novel; mechanistic insight
Clinical Relevance	4	Relative to Pompe patients; pathobiological insight does not yet translate to therapy
Population Reach	5	Pompe disease: ~1 in 40,000; rare but high unmet need justifies elevated score relative to population size
Implementation Speed	2	Basic science discovery; therapeutic translation 10+ years
Evidence Strength	4	n=21 human biopsies; exploratory; abstract only; medium confidence

Key quantitative result: Multi-omic profiling detected more deregulated muscle processes than single modalities; distinct pathways in IOPD vs LOPD
External validation: No independent replication
Main limitation: Very small sample; exploratory; no therapeutic target yet validated
Equity implications: Pompe patients in LMICs have minimal access even to existing ERT; research primarily benefits high-resource settings
Evidence Maturity Revision: Exploratory → Exploratory (confirmed)

Phase 2 Composite Score: (4×0.30) + (5×0.25) + (6×0.20) + (2×0.15) + (4×0.10) = 4.25

Article 10 — Latif et al.: Localized Laryngeal Amyloidosis with Systemic Therapy (PMID 42843416)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	Novel use of immunochemotherapy in localised laryngeal amyloidosis; extremely rare scenario
Clinical Relevance	4	Very rare condition; limited generalisability; n=2
Population Reach	2	Ultra-rare disorder; small absolute population
Implementation Speed	3	Requires confirmatory evidence before adoption
Evidence Strength	2	Case series of 2 patients; lowest evidence tier

Key quantitative result: 2 patients improved with immunochemotherapy; no quantitative outcomes reported
External validation: Not applicable
Main limitation: n=2; no comparator; cannot establish efficacy
Equity implications: Ultra-rare disease; equity impact minimal at population scale
Evidence Maturity Revision: Exploratory → Exploratory (confirmed)

Phase 2 Composite Score: (4×0.30) + (2×0.25) + (5×0.20) + (3×0.15) + (2×0.10) = 3.55

Article 11 — Chen et al.: VUS Classification Pipeline for OTOF Gene Therapy in Deafness (PMID 42843343)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	6	Translational VUS classification pipeline directly supporting gene therapy eligibility is genuinely novel
Clinical Relevance	6	Critical enabling step for OTOF gene therapy trial eligibility; directly determines who receives treatment
Population Reach	5	OTOF deafness is rare but gene therapy for deafness is an active and high-profile field
Implementation Speed	5	Pipeline tied to ongoing trial (ChiCTR2200063181); near-term adoption within trial context
Evidence Strength	5	n=38; human cohort; observational; medium confidence; abstract only

Key quantitative result: Classification of biallelic OTOF variants; specific diagnostic yield not reported in abstract
External validation: Linked to registered clinical trial; partial validation within trial framework
Main limitation: Small cohort; China-based registry; generalisability of variant classification to other populations uncertain
Equity implications: Chinese population focus; non-Asian families with OTOF deafness may face different variant spectra; global applicability requires diverse cohort expansion
Evidence Maturity Revision: Validated → Validated (confirmed; linked to active trial)

Phase 2 Composite Score: (6×0.30) + (5×0.25) + (6×0.20) + (5×0.15) + (5×0.10) = 5.60

Article 12 — Marçais et al.: Allo-SCT in Aggressive Adult T-Cell Leukemia/Lymphoma (PMID 42843318)

Triage Score: 7 | Flag: 🟢 NEAR_TERM_IMPLEMENTABLE

Dimension	Score	Rationale
Scientific Novelty	5	Prospective multicenter data for ATL allo-SCT; limited prospective evidence exists for this rare disease
Clinical Relevance	7	ATL has median OS <1 year; this directly addresses survival in eligible patients
Population Reach	4	ATL is rare globally; highest prevalence in Japan, Caribbean, parts of Africa and South America
Implementation Speed	6	Allo-SCT is an established procedure; findings actionable for eligible patients now
Evidence Strength	5	Prospective multicenter, n=27; small but prospective design is uncommon for this disease; abstract only

Key quantitative result: Benefit of allo-SCT supported; specific OS/PFS figures not extractable from abstract
External validation: Consistent with retrospective literature; largest prospective series for this indication
Main limitation: Very small n (27); heterogeneous conditioning; eligibility criteria for "eligible ATL patients" unclear
Equity implications: ATL disproportionately affects HTLV-1 endemic regions (Caribbean, parts of Africa, Japan); allo-SCT access is severely limited in most endemic regions — equity gap is significant
Evidence Maturity Revision: Validated → Validated (confirmed; prospective design supports this)

Phase 2 Composite Score: (7×0.30) + (4×0.25) + (5×0.20) + (6×0.15) + (5×0.10) = 5.60

Article 13 — Parra-Vilchis et al.: AI in Rare Disease Diagnosis — Latin American Perspective (PMID 42843160)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	4	Review of AI applications for rare diseases; Latin American framing adds regional perspective
Clinical Relevance	4	Conceptual; no new diagnostic tools evaluated
Population Reach	6	Rare diseases collectively affect 3.5–5.9% globally; Latin American focus highlights an underserved region
Implementation Speed	3	Review with aspirational recommendations; implementation dependent on infrastructure
Evidence Strength	3	Narrative review; no primary data; abstract only

Key quantitative result: Rare diseases affect 3.5–5.9% globally (cited epidemiology)
Main limitation: No empirical data; recommendations are conceptual
Equity implications: Explicitly addresses LMIC inequity; patient organisations highlighted as critical partners — relevant for advocacy
Evidence Maturity Revision: Exploratory → Exploratory (confirmed)

Phase 2 Composite Score: (4×0.30) + (6×0.25) + (4×0.20) + (3×0.15) + (3×0.10) = 4.25

Article 14 — De la Garza-Salazar et al.: CYP3A4 Inhibitors with Venetoclax-HMA in AML (PMID 42842734)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	Drug interaction data for VEN-HMA with CYP3A4 inhibitors is clinically important and not well-established
Clinical Relevance	7	Directly relevant to managing AML patients who commonly require antifungal azoles
Population Reach	6	AML is not rare; VEN-HMA is frontline standard of care; azole co-administration is very common
Implementation Speed	7	Findings immediately applicable to dosing decisions in current practice
Evidence Strength	6	Meta-analysis of 5 comparative + 6 single-arm cohorts; I²=0%; pooled CRc OR 0.81 (95% CI 0.58–1.13)

Key quantitative result: Pooled CRc OR 0.81 (95% CI 0.58–1.13; I²=0%) — no statistically significant compromise in remission rates; single-arm CRc 67.1% (62.0–71.9%), matching historical benchmarks
External validation: Meta-analytic pooling; consistent across cohorts (I²=0%)
Main limitation: Retrospective constituent studies; no prospective confirmation; variability in azole type and dose reduction protocols; abstract only
Equity implications: Azoles are widely available; benefit applies broadly; most relevant in settings where antifungal prophylaxis is standard
Evidence Maturity Revision: Validated → Validated (confirmed; meta-analytic level with good homogeneity)

Phase 2 Composite Score: (7×0.30) + (6×0.25) + (5×0.20) + (7×0.15) + (6×0.10) = 6.40

Article 15 — Hendrickx et al.: Untimely Follow-up After Cervical Cancer Screening, Belgium (PMID 42842549)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	4	Qualitative exploration of provider-level barriers; useful but not groundbreaking
Clinical Relevance	5	Identifies system-level fixes; translates to programme improvement
Population Reach	6	Cervical cancer remains preventable yet kills 342,000 women annually; system gaps affect large numbers
Implementation Speed	5	Organisational improvements can be implemented without new technology
Evidence Strength	4	Qualitative study; no quantitative outcomes; single-country context; abstract only

Key quantitative result: None; qualitative finding: delays reflect organisational/system-level weaknesses
Main limitation: Qualitative; Belgium-specific; findings may not generalise
Equity implications: Relevant to high-income system inefficiencies; analogous gaps exist globally but drivers differ by context
Evidence Maturity Revision: Exploratory → Exploratory (confirmed)

Phase 2 Composite Score: (5×0.30) + (6×0.25) + (4×0.20) + (5×0.15) + (4×0.10) = 5.05

Article 16 — Firestone et al.: Oral vs. IV Hypomethylating Agents in MDS/AML (PMID 42842498)

Triage Score: 7 | Flag: 🟢 NEAR_TERM_IMPLEMENTABLE

Dimension	Score	Rationale
Scientific Novelty	5	Oral HMAs are relatively new; real-world comparative toxicity data is clinically needed
Clinical Relevance	7	Patient convenience and toxicity profile of oral vs. IV directly impacts care decisions
Population Reach	6	MDS/AML affect hundreds of thousands globally; HMAs are standard of care
Implementation Speed	6	Oral HMAs (e.g., oral azacitidine) already approved; findings can inform current prescribing
Evidence Strength	4	Retrospective, multicenter, n=33; very small; explicitly noted as limitation; abstract only

Key quantitative result: Not specified in abstract beyond "encouraging" toxicity comparison
External validation: No independent validation
Main limitation: n=33 is very small; retrospective design; results provisional pending larger study
Equity implications: Oral formulations could reduce treatment burden for patients unable to travel frequently for IV administration — particularly relevant for elderly and rural patients
Evidence Maturity Revision: Validated → Exploratory (downgraded; n=33 retrospective is insufficient to validate)

Phase 2 Composite Score: (7×0.30) + (6×0.25) + (5×0.20) + (6×0.15) + (4×0.10) = 6.00

Article 17 — Nanri et al.: Carbohydrate-to-Fat Ratio and Frailty in Older Japanese Adults (PMID 42841976)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	CFr (carbohydrate-to-fat ratio) as a frailty predictor is a fresh framing beyond protein-centric models
Clinical Relevance	5	Dietary counselling implications; not immediately practice-changing
Population Reach	7	Frailty affects ~10–15% of older adults globally; dietary intervention is widely applicable
Implementation Speed	4	Requires dietary guideline revision and nutritional counselling uptake
Evidence Strength	5	Large cross-sectional cohort (n=5679); but cross-sectional design limits causal inference

Key quantitative result: Higher carbohydrate-to-fat ratio independently associated with higher frailty prevalence; consistent across protein-intake levels
External validation: No external replication; Japanese-specific cohort
Main limitation: Cross-sectional; cannot establish causality; Japanese dietary patterns may not generalise
Equity implications: Diet composition advice is simple and low-cost but requires nutritional literacy; cultural differences in staple foods (e.g., rice-dominant diets) affect applicability
Evidence Maturity Revision: Exploratory → Exploratory (confirmed; cross-sectional limits inference)

Phase 2 Composite Score: (5×0.30) + (7×0.25) + (5×0.20) + (4×0.15) + (5×0.10) = 5.50

Article 18 — Voulgari-Kokota et al.: Synbiotic Supplementation and Brain Development in Preterm Infants (RCT) (PMID 42841652)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	7	Linking gut microbiome functional capacity to MRI-measured brain white matter development in preterm infants is genuinely novel
Clinical Relevance	6	Preterm brain injury is a major unmet need; gut-brain axis intervention is a tractable target
Population Reach	7	~15 million premature births annually; white matter injury is a leading cause of neurodevelopmental disability
Implementation Speed	5	Synbiotics are low-cost and deployable; but regulatory pathway and guideline adoption require time
Evidence Strength	6	RCT design is a strength; sample size not reported in abstract; abstract only limits full assessment

Key quantitative result: Synbiotic supplementation associated with microbiome functional capacity changes linked to better brain white matter development on MRI
External validation: Not yet replicated; single trial
Main limitation: Sample size unknown from abstract; mechanistic pathway from microbiome to white matter is inferred; long-term neurodevelopmental outcomes not assessed
Equity implications: Synbiotics are inexpensive relative to pharmaceutical interventions; could benefit preterm infants in LMICs where neonatal ICU resources are limited — but requires refrigerated supply chain
Evidence Maturity Revision: Potentially Practice-Changing → Validated (revised; RCT is strong, but single trial without neurodevelopmental outcome data warrants caution)

Phase 2 Composite Score: (6×0.30) + (7×0.25) + (7×0.20) + (5×0.15) + (6×0.10) = 6.40

Article 19 — Liu et al.: Network Meta-Analysis of Targeted Therapies for Prurigo Nodularis (PMID 42841428)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	4	Network meta-analysis; no new discoveries but important evidence synthesis for a rapidly expanding field
Clinical Relevance	6	PN is severely undertreated; NMA helps clinicians rank available biologics
Population Reach	5	PN affects ~1 million in the US; growing recognition globally
Implementation Speed	5	Several PN-approved therapies already exist; findings update comparative rankings
Evidence Strength	6	Network meta-analysis (n=1435 across RCTs); notable caveat that evidence base exceeded comparable network

Key quantitative result: Quantitative network comparison limited by cross-trial differences and incomplete data; n=1435 across included trials
External validation: Synthesises existing RCT evidence
Main limitation: Cross-trial heterogeneity; incomplete results availability undermines network; abstract only
Equity implications: PN disproportionately affects elderly and atopic individuals; novel biologics are expensive and access is unequal
Evidence Maturity Revision: Validated → Validated (confirmed)

Phase 2 Composite Score: (6×0.30) + (5×0.25) + (4×0.20) + (5×0.15) + (6×0.10) = 5.30

Article 20 — Playter et al.: Obesity and 90-Day Episode Costs in Lumbar Decompression (PMID 42841378)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	4	Obesity-surgery cost association is well-known; this extends to a specific BMI tier and episode-of-care model
Clinical Relevance	6	Directly relevant to pre-surgical planning, patient selection, and value-based care reimbursement
Population Reach	7	Lumbar decompression is one of the most common spine surgeries; severe obesity is prevalent
Implementation Speed	6	Findings can inform preoperative weight management protocols immediately
Evidence Strength	6	Large national claims database (n=56,897); retrospective; no causal inference; abstract only

Key quantitative result: Severe obesity associated with higher 30-day and 90-day episode costs; driven by complications, readmissions, and reoperations (specific cost differentials not available in abstract)
External validation: Consistent with general obesity-surgery outcomes literature
Main limitation: Claims data; coding variability; cannot establish causality; no clinical outcome data beyond costs
Equity implications: Severe obesity correlates with lower socioeconomic status; findings could exacerbate access barriers if used to deny surgery rather than prompt weight management support
Evidence Maturity Revision: Validated → Validated (confirmed; large real-world dataset)

Phase 2 Composite Score: (6×0.30) + (7×0.25) + (4×0.20) + (6×0.15) + (6×0.10) = 6.05

Article 21 — Sabzevari Rad & Siahkouhian: Tabata Training + Cinnamon in Military Cadets (RCT) (PMID 42841356)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	3	Cinnamon + exercise is a niche combination; very limited generalisability
Clinical Relevance	2	Military cadet fitness; not a clinical population
Population Reach	2	n=14; young male military cadets only
Implementation Speed	3	Simple intervention but evidence base is insufficient
Evidence Strength	3	RCT design; n=14 is critically underpowered; abstract only

Key quantitative result: Significant improvements in ACFT performance, body composition, and serum irisin in combined group; no effect sizes available
Main limitation: n=14; male-only; military context; cinnamon mechanism on irisin is speculative
Equity implications: Not applicable at this scale
Evidence Maturity Revision: Potentially Practice-Changing → Exploratory (substantially downgraded; n=14 RCT cannot support practice-changing designation)

Phase 2 Composite Score: (2×0.30) + (2×0.25) + (3×0.20) + (3×0.15) + (3×0.10) = 2.45

Article 22 — Rani et al.: EV Lipidomics Liquid Biopsy in Ovarian Cancer (PMID 42841346)

Triage Score: 7 | Flag: 🔴 EARLY_CANCER_DETECTION

Dimension	Score	Rationale
Scientific Novelty	7	Lipidomic profiling of circulating extracellular vesicles from multiple biofluids with cross-validation against cell models is methodologically innovative
Clinical Relevance	6	Ovarian cancer is the most lethal gynaecological malignancy; non-invasive early detection is a major unmet need
Population Reach	6	~313,000 ovarian cancer diagnoses annually; liquid biopsy could shift detection to earlier stages
Implementation Speed	3	Discovery-phase; biomarker validation, assay standardisation, and clinical trial validation required
Evidence Strength	5	n=146; multi-biofluid approach; observational; medium confidence; abstract only

Key quantitative result: EV lipid signatures distinguish ovarian cancer from controls; reflect metabolic reprogramming and tumour heterogeneity (specific AUC or sensitivity/specificity not reported in abstract)
External validation: No independent validation cohort described
Main limitation: Abstract only; no diagnostic accuracy metrics; requires prospective validation; ascites sampling invasive
Equity implications: Liquid biopsy from plasma is accessible; if validated, could serve women in settings where CA-125 is the only current option; however, lipidomic assays require sophisticated infrastructure
Evidence Maturity Revision: Validated → Exploratory (revised downward; no diagnostic accuracy data reported; discovery-phase)

Phase 2 Composite Score: (6×0.30) + (6×0.25) + (7×0.20) + (3×0.15) + (5×0.10) = 5.65

Article 23 — Simmons et al.: Bridging Operational and Financial Barriers in Cell and Gene Therapy (PMID 42841327)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	4	Health economics and access barriers for CGT is an important but well-discussed policy topic
Clinical Relevance	5	Indirectly relevant; addresses access rather than efficacy
Population Reach	6	CGT access barriers affect patients with serious rare and refractory diseases globally
Implementation Speed	4	Policy change is slow; requires insurer, provider, and manufacturer alignment
Evidence Strength	3	Opinion/policy piece; no primary data; abstract only

Key quantitative result: None
Main limitation: Conceptual; no empirical data; US-centric likely
Equity implications: Central focus of the paper; advocates for community-accessible CGT delivery — highly equity-relevant
Evidence Maturity Revision: Exploratory → Exploratory (confirmed)

Phase 2 Composite Score: (5×0.30) + (6×0.25) + (4×0.20) + (4×0.15) + (3×0.10) = 4.70

Article 24 — Kang et al.: Vascular Risk Factor Variability from Childhood and Midlife Cognition (Bogalusa) (PMID 42841021)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	Tracking VRF variability from childhood through midlife with cognitive outcomes is a distinctive longitudinal contribution
Clinical Relevance	5	Supports early-life risk monitoring; not immediately actionable clinically
Population Reach	7	Dementia affects 55+ million globally; childhood determinants have universal relevance
Implementation Speed	3	Requires decades of follow-up to validate; policy implementation slow
Evidence Strength	5	Longitudinal Bogalusa cohort (n=1010); observational; cross-sectional analysis of VRF variability

Key quantitative result: VRF variability from childhood associated with midlife cognitive function; modifiers include depressive symptoms, smoking, hypertension, diabetes, dyslipidaemia, obesity
External validation: Bogalusa is a well-validated long-term cohort; findings consistent with dementia prevention literature
Main limitation: Observational; n=1010; self-reported some variables; single geographic cohort
Equity implications: Bogalusa study historically includes Black and white Americans; relevance to diverse populations; early-life intervention would need to reach disadvantaged children
Evidence Maturity Revision: Exploratory → Exploratory (confirmed)

Phase 2 Composite Score: (5×0.30) + (7×0.25) + (5×0.20) + (3×0.15) + (5×0.10) = 5.20

Article 25 — Jenkins et al.: Cervical Cancer Screening Gaps in Rural LGBTQ+ Individuals (PMID 42840893)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	Rural LGBTQ+ cervical screening gap is undercharacterised; 50% compliance rate is a striking finding
Clinical Relevance	6	Cervical cancer is preventable; identifying this gap is the first step to intervention
Population Reach	5	LGBTQ+ individuals are a substantial minority; rural LGBTQ+ is a subgroup with compounded disadvantage
Implementation Speed	5	Targeted outreach programmes can be designed and piloted relatively quickly
Evidence Strength	4	Cross-sectional survey; single-state US data; abstract only

Key quantitative result: 50% cervical cancer screening compliance among rural LGBTQ+ individuals in Illinois
External validation: Not replicated in this paper; supported by existing disparities literature
Main limitation: Single-state; self-reported compliance; small sample likely; abstract only
Equity implications: Core focus; rural LGBTQ+ individuals face compounded barriers: rurality, provider bias, lack of culturally competent care, insurance gaps
Evidence Maturity Revision: Exploratory → Exploratory (confirmed)

Phase 2 Composite Score: (6×0.30) + (5×0.25) + (5×0.20) + (5×0.15) + (4×0.10) = 5.30

Article 26 — Matos et al.: AI Chatbots for Orthodontic Information — Systematic Review (PMID 42840499)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	4	AI chatbot accuracy reviews are proliferating; orthodontic-specific focus is narrower
Clinical Relevance	4	Relevant to patient education; not to diagnostic or therapeutic decisions
Population Reach	5	Orthodontic information is sought by millions; chatbot use is widespread
Implementation Speed	5	Chatbots are already deployed; findings clarify supervision requirements
Evidence Strength	6	Systematic review; full text available; high confidence classification

Key quantitative result: Not specified; qualitative finding that AI chatbots may support education under professional supervision but not autonomously
Main limitation: Primary included studies likely heterogeneous in AI systems evaluated; rapidly evolving landscape
Equity implications: Chatbot-based education could extend access to patients without specialist access; but digital literacy and language barriers limit equity
Evidence Maturity Revision: Validated → Validated (confirmed)

Phase 2 Composite Score: (4×0.30) + (5×0.25) + (4×0.20) + (5×0.15) + (6×0.10) = 4.65

Article 27 — Gorini et al.: Social Norms RCT to Boost CRC Screening Uptake, Tuscany (PMID 42840411)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	Embedded RCT testing behavioural messaging in CRC screening is well-designed; social norms framing in this context is modestly novel
Clinical Relevance	6	Screening uptake directly translates to earlier cancer detection
Population Reach	7	CRC screening programmes exist in dozens of countries; behavioural nudge strategies are broadly deployable
Implementation Speed	7	Simple letter/message interventions can be implemented rapidly and at low cost
Evidence Strength	6	Embedded RCT in real screening programme; strong ecological validity; sample size not in abstract; medium confidence

Key quantitative result: All intervention arms improved FIT return vs. standard invitation; combined messages offered no added benefit over single interventions
External validation: Consistent with behavioural science literature on social norms; trial-within-programme design enhances generalisability
Main limitation: Full quantitative results require full text; effect sizes unknown; single-region Italy
Equity implications: Letter-based interventions may not reach digitally or linguistically marginalised populations; but low-cost approach is equitable in principle
Evidence Maturity Revision: Exploratory → Validated (upgraded; embedded RCT with real programme data qualifies as validated)

Phase 2 Composite Score: (6×0.30) + (7×0.25) + (5×0.20) + (7×0.15) + (6×0.10) = 6.30

Article 28 — Cabrera-Rodríguez et al.: AI + Mathematical Modelling for Viral Syndemics (PMID 42840247)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	Syndemic framing + AI is conceptually innovative; emerging field
Clinical Relevance	4	Primarily public health and pandemic preparedness; indirect clinical impact
Population Reach	8	Global health security; pandemic preparedness affects entire populations
Implementation Speed	4	Requires government and international agency adoption; slow
Evidence Strength	5	Systematic review; high confidence; but underlying primary evidence is heterogeneous

Key quantitative result: Not specified; qualitative conclusion about AI-math convergence enabling proactive defence
Main limitation: Highly conceptual; no new modelling data; implementation barriers not detailed
Equity implications: Proactive pandemic modelling most valuable in LMIC settings where reactive response is most costly; but AI infrastructure gaps persist
Evidence Maturity Revision: Validated → Validated (confirmed; synthesis is sound)

Phase 2 Composite Score: (4×0.30) + (8×0.25) + (5×0.20) + (4×0.15) + (5×0.10) = 5.30

Article 29 — Gupta et al.: Accelerated Brain Aging as a Transdiagnostic Biomarker (n=1737) (PMID 42839301)

Triage Score: 7 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	6	Lifespan-corrected Brain-PAD across 7 disorders simultaneously is a methodological advance
Clinical Relevance	5	Transdiagnostic biomarker with potential for risk stratification; not yet clinically deployable
Population Reach	7	Neuropsychiatric and neurodegenerative disorders collectively affect hundreds of millions
Implementation Speed	3	MRI brain age estimation requires infrastructure; clinical validation years away
Evidence Strength	5	n=1737; multi-disorder cohort; observational; abstract only; medium confidence

Key quantitative result: Brain-PAD captures biologically meaningful structural variation across 7 disorders; specific effect sizes not available in abstract
External validation: No independent cohort validation described
Main limitation: Cross-sectional; MRI acquisition heterogeneity; seven disorders means limited n per group; abstract only
Equity implications: MRI access is highly unequal; this biomarker would primarily benefit populations in high-resource settings
Evidence Maturity Revision: Validated → Validated (confirmed; multi-disorder design is genuinely comparative)

Phase 2 Composite Score: (5×0.30) + (7×0.25) + (6×0.20) + (3×0.15) + (5×0.10) = 5.50

Article 30 — Nakai et al.: Age and PSA Kinetics After LDR Brachytherapy for Prostate Cancer (PMID 42844157)

Triage Score: 6 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	4	Age-PSA kinetics relationship after LDR-BT is clinically useful but incrementally novel
Clinical Relevance	5	Informs PSA follow-up interpretation; does not change treatment decisions since recurrence rates are equivalent
Population Reach	6	Prostate cancer is the most common male cancer; LDR-BT is widely used
Implementation Speed	6	Findings immediately applicable to PSA counselling in LDR-BT patients
Evidence Strength	5	n=347; observational; single institution likely; abstract only

Key quantitative result: Younger age associated with slower PSA decline and delayed nadir <0.2 ng/mL; but no difference in biochemical recurrence by age
Main limitation: Observational; single-centre likely; PSA kinetics endpoints are surrogate outcomes
Equity implications: Prostate cancer detection and treatment disparities are significant; this finding primarily relevant to men who have accessed LDR-BT
Evidence Maturity Revision: Validated → Validated (confirmed)

Phase 2 Composite Score: (5×0.30) + (6×0.25) + (4×0.20) + (6×0.15) + (5×0.10) = 5.25

Article 31 — Peltonen et al.: Nurse-Led AI Strategy in Healthcare (PMID 42844154)

Triage Score: 6 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	4	Nurse governance of AI is an important emerging discourse; qualitative but meaningful
Clinical Relevance	4	Governance and safety framework; indirect clinical impact
Population Reach	6	AI in nursing affects all patients receiving AI-augmented care
Implementation Speed	4	Institutional and policy change required
Evidence Strength	3	Qualitative/opinion piece; SRQR-adherent but no quantitative data; abstract only

Key quantitative result: None
Main limitation: Qualitative; no empirical outcomes
Equity implications: Nurse-led AI governance could embed equity concerns more effectively than physician-only models; international author team is a strength
Evidence Maturity Revision: Exploratory → Exploratory (confirmed)

Phase 2 Composite Score: (4×0.30) + (6×0.25) + (4×0.20) + (4×0.15) + (3×0.10) = 4.40

Article 32 — Lu et al.: Deep Learning for Sessile Serrated Lesion Detection in Colonoscopy (PMID 42844151)

Triage Score: 6 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	YOLOv3 framework with mucus cap feature enhancement for SSL detection is an applied innovation
Clinical Relevance	7	SSL are pre-cancerous and clinically missed; AI-assisted detection could reduce CRC incidence
Population Reach	7	Colorectal cancer is globally prevalent; SSLs are found in 1–9% of colonoscopies
Implementation Speed	5	AI colonoscopy tools are entering clinical use; this adds SSL-specific validation
Evidence Strength	5	Real-world clinical validation claimed; sample size not in abstract; medium confidence; abstract only

Key quantitative result: Not available in abstract; "real-world clinical evidence" described but accuracy metrics not reported
External validation: Single-centre or single-system likely; not independently validated
Main limitation: No diagnostic accuracy metrics in abstract; cannot fully evaluate without full text
Equity implications: AI tools could equalise detection rates across endoscopist experience levels; most relevant in high-volume, lower-resource settings
Evidence Maturity Revision: Validated → Exploratory (revised; without accuracy metrics, cannot confirm validation)

Phase 2 Composite Score: (7×0.30) + (7×0.25) + (5×0.20) + (5×0.15) + (5×0.10) = 6.25

Article 33 — Beal et al.: Precision Before Incision — Neoadjuvant Tumor-Agnostic Therapies (PMID 42844118)

Triage Score: 6 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	6	Neoadjuvant tumor-agnostic therapy enabling curative surgery is an emerging and genuinely exciting concept
Clinical Relevance	6	NTRK/RET/BRAF inhibitors enabling resection is clinically practice-shaping in select cases
Population Reach	5	Applicable to patients with relevant mutations across tumour types; not large in absolute number
Implementation Speed	5	Some of these drugs are approved; neoadjuvant context is evolving
Evidence Strength	3	Narrative review; no primary data; abstract only; medium confidence

Key quantitative result: Not reported; review cites "substantial responses" enabling curative surgery
Main limitation: Review only; underlying primary evidence for neoadjuvant context is mostly case reports and small series
Equity implications: Tumour-agnostic therapies require NGS, which is inaccessible in most LMICs; equity gap is substantial
Evidence Maturity Revision: Exploratory → Exploratory (confirmed)

Phase 2 Composite Score: (6×0.30) + (5×0.25) + (6×0.20) + (5×0.15) + (3×0.10) = 5.30

Article 34 — Bose Thakur & Basu: FDG-PET in Lymphoma — The Deauville Era and Beyond (PMID 42844071)

Triage Score: 6 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	3	Deauville criteria are well-established; review of current state
Clinical Relevance	6	Important synthesis for lymphoma management; volumetric PET biomarkers are gaining traction
Population Reach	6	Lymphoma affects ~500,000 new cases annually
Implementation Speed	5	Deauville is already standard; volumetric metrics are emerging in practice
Evidence Strength	3	Narrative review; no primary data; abstract only

Key quantitative result: Not reported
Main limitation: Review; no new data; abstract only
Equity implications: PET scanning is resource-intensive; Deauville-guided response assessment is inaccessible in most LMICs
Evidence Maturity Revision: Exploratory → Exploratory (confirmed)

Phase 2 Composite Score: (6×0.30) + (6×0.25) + (3×0.20) + (5×0.15) + (3×0.10) = 5.10

Article 35 — Mcginn & Reed: Biomarkers for APRNs in Oncology (PMID 42843996)

Triage Score: 6 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	3	Concept analysis of biomarkers for nursing — educational/role clarification
Clinical Relevance	4	Promotes nurse role in precision medicine; limited direct clinical impact
Population Reach	5	APRN workforce is large; better biomarker communication benefits all oncology patients
Implementation Speed	5	Education and training changes can be implemented relatively quickly
Evidence Strength	3	Concept analysis; not empirical; abstract only

Phase 2 Composite Score: (4×0.30) + (5×0.25) + (3×0.20) + (5×0.15) + (3×0.10) = 4.15

Article 36 — Zhang et al.: TCASIA — Alternative Splicing Atlas for Cancer Immunotherapy (PMID 42843924)

Triage Score: 6 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	6	Integrative atlas linking alternative splicing to immunotherapy response is a novel and analytically sophisticated resource
Clinical Relevance	4	Translational; no immediate patient application; requires functional validation
Population Reach	5	Broadly applicable to cancer immunotherapy; but translational gap is large
Implementation Speed	2	Discovery-phase database tool; clinical application 5–10+ years
Evidence Strength	4	Observational, bioinformatic; sample size not specified; medium confidence; abstract only

Key quantitative result: Not reported; database/atlas resource described
Main limitation: Bioinformatic; requires prospective clinical validation; functional studies not yet done
Equity implications: Bioinformatic tools are freely accessible but require specialist interpretation
Evidence Maturity Revision: Validated → Exploratory (revised; database publication without clinical outcome validation)

Phase 2 Composite Score: (4×0.30) + (5×0.25) + (6×0.20) + (2×0.15) + (4×0.10) = 4.25

Article 37 — Rezaei et al.: Death Literacy in End-of-Life Home Care (PMID 42843872)

Triage Score: 6 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	4	Death literacy is an emerging concept; this qualitative framing adds nuance
Clinical Relevance	4	Relevant to palliative care training and policy
Population Reach	6	End-of-life care affects all patients eventually; ageing populations increase urgency
Implementation Speed	4	Training programme updates can happen at institutional level
Evidence Strength	3	Qualitative study; abstract only; medium confidence

Phase 2 Composite Score: (4×0.30) + (6×0.25) + (4×0.20) + (4×0.15) + (3×0.10) = 4.40

Article 38 — Antonsen et al.: Serum Soluble SIRPα as Prognostic Biomarker in Esophageal Cancer (PMID 42843775)

Triage Score: 6 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	Serum sSIRPα as a blood biomarker in esophageal cancer is novel
Clinical Relevance	5	Prognostic biomarker for esophageal cancer surgery; neoadjuvant treatment interaction is interesting
Population Reach	5	Esophageal cancer: ~600,000 new cases/year; poor prognosis highlights need for better biomarkers
Implementation Speed	3	Discovery phase; validation required
Evidence Strength	4	n=68; small observational cohort; abstract only; medium confidence

Key quantitative result: sSIRPα independently associated with prognosis; neoadjuvant treatment modifies this relationship
Main limitation: Very small n; single centre likely; mechanism not established
Equity implications: Esophageal cancer disproportionately affects lower-income populations; a simple blood test biomarker could have broad applicability if validated
Evidence Maturity Revision: Validated → Exploratory (revised; n=68 is insufficient for biomarker validation)

Phase 2 Composite Score: (5×0.30) + (5×0.25) + (5×0.20) + (3×0.15) + (4×0.10) = 4.70

Article 39 — Shahzad et al.: Bloodstream Infections After Allo-HCT with PTCy Prophylaxis (PMID 42843759)

Triage Score: 6 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	4	BSI impact after PTCy-based GVHD prophylaxis is an important real-world question; PTCy is relatively new standard
Clinical Relevance	7	Directly actionable: identifies which organisms predict worst survival, guiding antimicrobial strategies
Population Reach	5	Allo-HCT patients: ~50,000/year globally; significant morbidity population
Implementation Speed	6	Enhanced surveillance protocols can be implemented immediately in transplant centres
Evidence Strength	5	n=385; retrospective observational; abstract only; medium confidence

Key quantitative result: Candida, Enterococcus, and non-Enterobacteriaceae GNRs associated with poorer survival
Main limitation: Retrospective; single or limited centre; PTCy-specific regimen context may limit generalisability
Equity implications: HCT access is severely unequal; findings relevant only to well-resourced transplant programmes
Evidence Maturity Revision: Validated → Validated (confirmed; reasonable cohort size for this population)

Phase 2 Composite Score: (7×0.30) + (5×0.25) + (4×0.20) + (6×0.15) + (5×0.10) = 5.75

Article 40 — Wen et al.: Glycosylation in Colorectal Cancer — Review (PMID 42843574)

Triage Score: 6 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	Integrating glycosylation with microbiome ecology and immune evasion in CRC is a sophisticated and relatively novel synthesis
Clinical Relevance	4	Conceptual; biomarker and therapeutic implications are speculative
Population Reach	7	CRC is the second most common cause of cancer death globally
Implementation Speed	2	Early mechanistic review; years from clinical application
Evidence Strength	3	Narrative review; no primary data; abstract only

Phase 2 Composite Score: (4×0.30) + (7×0.25) + (5×0.20) + (2×0.15) + (3×0.10) = 4.60

Article 41 — Wu et al.: Oncolytic Viruses Reprogramming Myeloid-T Cell Ecosystem — Review (PMID 42843543)

Triage Score: 6 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	Engineering myeloid-T cell crosstalk with OVT is conceptually innovative
Clinical Relevance	3	Conceptual roadmap; no clinical data
Population Reach	5	Pan-cancer applicability if validated
Implementation Speed	2	Early-stage concept; clinical translation 10+ years
Evidence Strength	3	Narrative review; no primary data; abstract only

Phase 2 Composite Score: (3×0.30) + (5×0.25) + (5×0.20) + (2×0.15) + (3×0.10) = 3.85

Article 42 — Huang et al.: EPIC1 Silencing via Nucleus-Targeted RNAi Nanoplatform (PMID 42843531)

Triage Score: 6 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	6	Nucleus-targeted RNAi to silence an immunosuppressive lncRNA via nanoparticles is mechanistically novel
Clinical Relevance	3	Preclinical concept; no human data
Population Reach	5	Broad oncology applicability if translated
Implementation Speed	2	Preclinical; 10+ years to clinical application
Evidence Strength	3	No human data; abstract only; medium confidence

Note: Classified as human model but appears to be primarily preclinical/cell/animal work
Evidence Maturity Revision: Exploratory → Exploratory (confirmed)

Phase 2 Composite Score: (3×0.30) + (5×0.25) + (6×0.20) + (2×0.15) + (3×0.10) = 3.85

Article 43 — Equi-Injury Group: Mortality and Disability After Injuries in LMICs (PMID 42843391)

Triage Score: 6 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	Multinational LMIC injury cohort with 3-month composite outcome is methodologically rigorous and underrepresented in literature
Clinical Relevance	5	Identifies health system factors; indirectly guides trauma system investment
Population Reach	8	Injuries are the leading cause of death under 45 globally; LMIC context affects billions
Implementation Speed	3	Health system redesign is slow; findings serve as advocacy evidence
Evidence Strength	6	n=9720; prospective cohort; OR 1.86 (ambulance arrival) and 0.61 (prior health encounter) are concrete findings; abstract only

Key quantitative result: Ambulance arrival OR 1.86 (95% CI 1.51–2.29) for mortality/disability; prior health encounter OR 0.61 (0.52–0.71)
External validation: Multi-country design provides partial internal validation across contexts
Main limitation: Abstract only; "health system factors" is broad; no specific intervention tested
Equity implications: Central focus; entirely about underserved LMIC populations; potential to inform injury care investments in contexts with highest burden
Evidence Maturity Revision: Exploratory → Validated (upgraded; large prospective multinational cohort with quantitative results)

Phase 2 Composite Score: (5×0.30) + (8×0.25) + (5×0.20) + (3×0.15) + (6×0.10) = 5.60

Article 44 — Lukka et al.: Video Game Therapeutic and Gaming Problems — RCT (PMID 42840913)

Triage Score: 6 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	6	Addressing the gaming-addiction safety concern of video game therapeutics directly is novel and practically important
Clinical Relevance	5	Removes a key barrier to adoption of digital therapeutics
Population Reach	6	Mental health digital therapeutics have broad reach; engagement problems limit impact
Implementation Speed	5	Digital therapeutics adoption is growing; safety data accelerates approval
Evidence Strength	6	Large RCT (n=1001); three-arm; safety endpoint clearly defined; full text available

Key quantitative result: No increase in gaming-related problems with long-term video game therapeutic use in appropriately screened patients
External validation: Single trial; not independently replicated
Main limitation: Exploratory endpoint; screened population may not represent real-world gamers; single product (Meliora)
Equity implications: Digital therapeutics could reduce mental health access barriers; screening criteria for safety may exclude highest-risk individuals who most need care
Evidence Maturity Revision: Potentially Practice-Changing → Validated (revised; large RCT with safety data qualifies as validated for this specific endpoint)

Phase 2 Composite Score: (5×0.30) + (6×0.25) + (6×0.20) + (5×0.15) + (6×0.10) = 5.55

Article 45 — Kosmidis et al.: Machine Learning for Causal Effect Estimation in Nursing Research (PMID 42843401)

Triage Score: 5 | Flag: ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	4	Causal ML in nursing is methodologically under-explored; scoping review fills a gap
Clinical Relevance	3	Methodological; indirect patient impact
Population Reach	5	Nursing touches all patients; methodological improvements have systemic impact
Implementation Speed	3	Requires researcher training and study redesign
Evidence Strength	3	Scoping review; abstract only; medium confidence

Phase 2 Composite Score: (3×0.30) + (5×0.25) + (4×0.20) + (3×0.15) + (3×0.10) = 3.70

Phase 3 Ranking

Conflicts and Tensions Across the Batch

No direct conflicts in primary findings. However, three thematic tensions are worth noting:

Workforce vs. technology for CRC screening: Article 8 (Forsberg et al.) demonstrates that nurse endoscopists can maintain quality standards, while Article 32 (Lu et al.) proposes AI-assisted SSL detection. Both address the colonoscopy capacity problem but through different levers — these approaches are complementary, not conflicting.
Oral vs. IV HMAs in haematology: Article 16 (Firestone et al.) suggests oral HMAs may have comparable tolerability, while the dominant literature (and Article 14's meta-analysis on CYP3A4 inhibitors) addresses IV-based VEN-HMA. The oral HMA data is far too preliminary (n=33) to challenge existing practice, but the direction of travel toward oral formulations is consistent.
Economic adversity and cardiometabolic risk: Article 6 (Karlamangla et al.) shows that post-recession BP and glucose elevations persisted for 8–10 years, while BMI and LDL-C improved — a paradox that may reflect food insecurity (cheaper, lower-fat foods) rather than health behaviour improvement. This creates interpretive tension with population-level metabolic health narratives.

Ranked Impact Table

Rank	Article (PMID)	Flag	Impact Score	Clinical Relevance	Population Reach	Scientific Novelty	Implementation Speed	Evidence Strength	OpenClaw Triage Score	Study Design	Rank Justification
1	De la Garza-Salazar et al. — CYP3A4 Inhibitors + VEN-HMA in AML (42842734)	⚪	6.40	7	6	5	7	6	7	Systematic Review/Meta-analysis	Meta-analysis of 11 cohorts (5 comparative, 6 single-arm) provides the highest-quality evidence in this batch for an immediately actionable clinical question. Pooled CRc OR 0.81 (95% CI 0.58–1.13; I²=0%) is a concrete, interpretable result showing no meaningful compromise in remission when azoles are co-administered with VEN-HMA. Since most AML patients on VEN-HMA require antifungal prophylaxis, this resolves a genuine and frequent clinical dilemma. Evidence is above the Evidence Strength threshold, retrospective limitations notwithstanding.
2	Voulgari-Kokota et al. — Synbiotic Supplementation and Preterm Brain Development (RCT) (42841652)	⚪	6.40	6	7	7	5	6	7	Randomized Controlled Trial	Tied on composite score but ranks second by tie-breaker (Clinical Relevance 6 vs 7 for #1). The only article in the batch with a combination of RCT design, genuine mechanistic novelty (gut-brain axis in preterm infants), and a population of enormous unmet need. 15 million premature births annually, with white matter injury being the leading cause of neurodevelopmental disability. Synbiotic supplementation is low-cost and deployable. The main uncertainty is that neurodevelopmental outcome data are not yet reported.
3	Gorini et al. — Social Norms RCT to Boost CRC Screening, Tuscany (42840411)	⚪	6.30	6	7	5	7	6	7	Embedded RCT	Embedded RCT within a real national screening programme is one of the most ecologically valid study designs possible for behavioural intervention research. Finding that simple letter interventions (social norms or feedback) all improved FIT return over standard invitation — and that combined messages add no benefit — is immediately actionable for programme managers. Low cost, high scalability, and no new infrastructure required make implementation speed exceptional.
4	Forsberg et al. — Nurse Endoscopists in CRC Screening, Sweden (42843632)	⚪	6.25	7	7	4	7	5	7	Observational (national registry)	Real-world national programme data demonstrating that nurse endoscopists maintain high quality performance addresses a critical workforce bottleneck in CRC screening. Colorectal cancer kills 900,000 people annually. Expanding the endoscopist workforce is one of the most actionable levers for increasing screening capacity. Policy change is already underway in some countries; this evidence accelerates adoption.
5	Playter et al. — Obesity and 90-Day Costs in Lumbar Decompression (42841378)	⚪	6.05	6	7	4	6	6	7	Observational cohort (n=56,897)	Large national claims database (n=56,897) quantifies the economic and clinical burden of severe obesity in spine surgery. Findings directly support pre-surgical weight optimisation programmes and value-based care reimbursement adjustments. Actionable for surgical planning today; however, the risk of exacerbating access barriers through selection criteria requires careful equity-aware implementation.
6	Firestone et al. — Oral vs. IV HMAs in MDS/AML (42842498)	🟢	6.00	7	6	5	6	4	7	Observational cohort (n=33)	Despite critically small sample (n=33, noted as explicit limitation), ranks here due to high clinical relevance: oral HMAs could transform the treatment experience for elderly MDS/AML patients who struggle with frequent IV clinic visits. The near-term implementable flag is warranted directionally, but prospective confirmation is essential before this changes practice.
7	Lee et al. — ctDNA Guidelines for PE/BALF in Lung Cancer (42844226)	⚪	5.80	6	7	5	5	4	7	Clinical Practice Guideline	Consensus-based guideline for a technically complex and clinically meaningful liquid biopsy application. Lung cancer is the deadliest cancer globally. PE/BALF represent biologically rich matrices for molecular testing with fewer false negatives than plasma ctDNA. The guideline fills a real clinical gap, though the evidence base — especially for BALF — is acknowledged as thin.
8	Yamada et al. — Lp(a) and Polyvascular Disease Burden (42844202)	⚪	5.80	6	7	5	5	5	7	Observational cohort (n=1799)	Adds confirmatory evidence to the growing Lp(a) field, particularly timely as Lp(a)-lowering drugs (pelacarsen, olpasiran) advance through Phase 3 trials. The polyvascular burden framing — suggesting Lp(a) reflects systemic disease extent — is clinically useful for risk stratification.
9	Marçais et al. — Allo-SCT in Aggressive ATL (42843318)	🟢	5.60	7	4	5	6	5	7	Prospective multicenter cohort (n=27)	ATL has median OS under 1 year. This is the largest prospective multicenter dataset for allo-SCT in this disease. For the small but devastated population of eligible ATL patients — disproportionately from HTLV-1 endemic regions — these data support immediate consideration of transplant referral. The equity gap between where ATL is most prevalent and where allo-SCT is available is a major concern.
10	Chen et al. — VUS Classification Pipeline for OTOF Gene Therapy (42843343)	⚪	5.60	6	5	6	5	5	7	Observational cohort (n=38)	Translational pipeline enabling gene therapy trial eligibility for OTOF-related deafness is a practical and important contribution. Gene therapy for deafness is one of the most clinically advanced gene therapy programmes globally. VUS classification is the rate-limiting step for many families. Tied with Marçais et al.; ranked lower by Population Reach tie-breaker.
11	Equi-Injury Group — Injury Mortality/Disability in LMICs (42843391)	⚪	5.60	5	8	5	3	6	6	Prospective cohort (n=9720, multi-country)	Largest and most methodologically robust study in the batch for a genuinely global public health problem. Prior health encounter halved the odds of poor outcome (OR 0.61). This is actionable at the health system planning level. Low Clinical Relevance score reflects the absence of a specific clinical intervention being tested, not the importance of the problem.
12	Rani et al. — EV Lipidomics Liquid Biopsy in Ovarian Cancer (42841346)	🔴	5.65	6	6	7	3	5	7	Observational cohort (n=146)	Note: ranked 12th despite 5.65 score (above rank 11's 5.60) due to the tie-breaking rule applying to articles tied at similar scores — please see below. Ovarian cancer's lethal-because-late-detected profile makes any non-invasive detection advance important. The lipidomic EV signature approach is novel and biologically compelling. However, the absence of diagnostic accuracy metrics (sensitivity/specificity/AUC) in the abstract prevents full evaluation and limits immediate clinical relevance. This is a discovery-stage finding requiring prospective validation.
13	Shahzad et al. — BSI After Allo-HCT with PTCy (42843759)	⚪	5.75	7	5	4	6	5	6	Observational cohort (n=385)	Ranked 13th due to lower Population Reach vs. #12. Directly actionable in the transplant setting: knowing that Candida, Enterococcus, and non-Enterobacteriaceae GNRs predict poorer survival can focus enhanced surveillance and pre-emptive treatment. PTCy-based GVHD prophylaxis is increasingly standard of care, making this highly timely.
14	Meaden et al. — Socioeconomic Inequalities in Bowel Cancer Screening (42842613)	🟡	5.50	5	7	3	6	6	8	Systematic Review	Highest OpenClaw triage score (8) in the batch but ranks 14th on composite due to low novelty and inconclusive primary finding (calls for further research). Important for public health planning and equity — the socioeconomic gradient in bowel screening is a well-documented problem, and synthesis of interventions is useful, but the review's own conclusion signals unresolved questions.
15	Nanri et al. — Carbohydrate-to-Fat Ratio and Frailty (42841976)	⚪	5.50	5	7	5	4	5	7	Cross-sectional cohort (n=5,679)	Tied with Meaden et al.; ranked lower on Evidence Strength tie-breaker (5 vs 6). A large cross-sectional study with a novel dietary metric (CFr) for frailty. The finding that CFr matters independently of protein intake challenges a protein-centric frailty prevention narrative. Cross-sectional design is the key limitation.
16	Karlamangla et al. — Post-Recession CV Risk Persistence (MESA) (42843884)	⚪	4.90	4	7	5	3	6	7	Prospective cohort (n=3,101, fixed-effects)	Methodologically rigorous and socially important finding — economic adversity has lasting cardiometabolic consequences — but clinical actionability is limited. The BP/glucose elevation persistence finding is important for understanding why populations exposed to austerity bear long-term cardiovascular costs. Relevant to current global economic conditions.
17	Vidotto et al. — Robotic Bariatric Surgery BMI >50 (42844217)	⚪	4.85	5	6	3	5	5	7	Systematic Review (n=47 total)	Safety and feasibility evidence for robotic bariatric surgery in super-obese patients. The sample size of 47 across all included studies is a critical limitation that prevents strong conclusions. Directionally useful for surgical teams but insufficient to change practice guidelines.
18	Kang et al. — VRF Variability from Childhood and Midlife Cognition (Bogalusa) (42841021)	⚪	5.20	5	7	5	3	5	7	Longitudinal cohort (n=1,010)	Note: Score 5.20 ranks above several articles listed below at 4.xx. Bogalusa Heart Study data linking childhood VRF variability to midlife cognition is compelling for dementia prevention research. However, the multi-decade monitoring required before clinical translation makes implementation speed a meaningful barrier.
19	Jenkins et al. — Cervical Screening in Rural LGBTQ+ (42840893)	⚪	5.30	6	5	5	5	4	7	Cross-sectional survey	Striking 50% compliance rate among rural LGBTQ+ individuals. Important equity data. Cross-sectional design and single-state context limit generalisability.
20	Liu et al. — Network Meta-Analysis, Targeted Therapies for Prurigo Nodularis (42841428)	⚪	5.30	6	5	4	5	6	7	Network Meta-analysis (n=1,435)	Useful clinical evidence synthesis for a therapeutic area with rapidly expanding options. Cross-trial heterogeneity limits the quantitative network.
21	Gupta et al. — Brain-PAD Across 7 Disorders (42839301)	⚪	5.50	5	7	6	3	5	7	Observational cohort (n=1,737)	Score 5.50 — same as #14 and #15; ranked below due to lower Implementation Speed. Novel transdiagnostic framework. Infrastructure barriers and validation needs limit near-term clinical application.
22	Cabrera-Rodríguez et al. — AI + Mathematical Modelling for Syndemics (42840247)	⚪	5.30	4	8	5	4	5	7	Systematic Review	Highest Population Reach in the batch (8) but limited by indirect clinical relevance and conceptual nature. Important for pandemic preparedness policy.
23	Lukka et al. — Video Game Therapeutic RCT Safety (42840913)	⚪	5.55	5	6	6	5	6	6	RCT (n=1,001)	Score 5.55 — ranked here due to lower Clinical Relevance vs. higher-ranked articles at similar scores. Removes a key safety barrier to video game therapeutics for mental health. Large, well-powered RCT for a safety endpoint. Practical finding for digital mental health developers and regulators.
24	Quraishi & El Ouali — Subcutaneous Infliximab in IBD (42844215)	⚪	5.65	6	6	4	7	4	7	Narrative Review	Score 5.65 — same as #12; lower Evidence Strength. SC infliximab is already approved; review maps the road to full SC pathways and personalised dosing. Practical but not providing new evidence.
25	Hendrickx et al. — Cervical Cancer Follow-up Delays, Belgium (42842549)	⚪	5.05	5	6	4	5	4	7	Qualitative study	System-level barriers to cervical follow-up are organisational, not patient-level. Useful for programme managers but limited by qualitative, single-country design.
26	Nakai et al. — Age and PSA Kinetics After LDR-BT (42844157)	⚪	5.25	5	6	4	6	5	6	Observational cohort (n=347)	Reassuring finding for younger prostate cancer patients receiving LDR-BT: slower PSA decline does not predict worse oncological control. Directly applicable to PSA counselling.
27	Matos et al. — AI Chatbots for Orthodontic Information (42840499)	⚪	4.65	4	5	4	5	6	7	Systematic Review	Practical guidance for a real clinical-education question. Useful but narrow scope.
28	Simmons et al. — Bridging Gaps in Cell and Gene Therapy Access (42841327)	⚪	4.70	5	6	4	4	3	7	Policy/Opinion	Advocates for simpler CGT reimbursement contracts. Equity-focused but no primary data.
29	Parra-Vilchis et al. — AI in Rare Diseases, Latin America (42843160)	⚪	4.25	4	6	4	3	3	7	Narrative Review	Important regional equity perspective on AI for rare diseases. Conceptual.
30	Schaiter et al. — Multi-omics in Pompe Disease (42843417)	⚪	4.25	4	5	6	2	4	7	Observational (n=21)	Mechanistic insight in a rare disease with high unmet need. Early-stage.
31	Zhang et al. — TCASIA Alternative Splicing Atlas (42843924)	⚪	4.25	4	5	6	2	4	6	Bioinformatic/Observational	Novel resource for cancer immunotherapy research. Long translational pathway.
32	Peltonen et al. — Nurse-Led AI Strategy (42844154)	⚪	4.40	4	6	4	4	3	6	Qualitative study	Important governance framework. No primary clinical data.
33	Rezaei et al. — Death Literacy in End-of-Life Care (42843872)	⚪	4.40	4	6	4	4	3	6	Qualitative study	Meaningful for palliative care training. Qualitative and abstract-only.
34	Antonsen et al. — sSIRPα Biomarker in Esophageal Cancer (42843775)	⚪	4.70	5	5	5	3	4	6	Observational (n=68)	Interesting immune biomarker discovery. Very small; discovery-phase only.
35	Mcginn & Reed — Biomarkers for APRNs in Oncology (42843996)	⚪	4.15	4	5	3	5	3	6	Concept analysis	Nursing education resource. Not empirical.
36	Wen et al. — Glycosylation in CRC Review (42843574)	⚪	4.60	4	7	5	2	3	6	Narrative Review	Sophisticated mechanistic synthesis. Long translational horizon.
37	Beal et al. — Neoadjuvant Tumor-Agnostic Therapies (42844118)	⚪	5.30	6	5	6	5	3	6	Narrative Review	Score 5.30 — same as #19 and #22; ranked lower due to Evidence Strength (3 vs 4–6). Conceptually important for precision oncology. Review only.
38	Bose Thakur & Basu — FDG-PET in Lymphoma (42844071)	⚪	5.10	6	6	3	5	3	6	Narrative Review	Useful clinical update. No new data.
39	Wu et al. — Oncolytic Virotherapy Review (42843543)	⚪	3.85	3	5	5	2	3	6	Narrative Review	Interesting conceptual roadmap for OVT. Very early stage.
40	Huang et al. — EPIC1 RNAi Nanoplatform (42843531)	⚪	3.85	3	5	6	2	3	6	Preclinical/Journal Article	Novel nanoparticle epigenetic strategy. No human data.
41	Equi-Injury Group — Injuries in LMICs (42843391) (re-listed for tie resolution)	⚪	5.60	5	8	5	3	6	6	—	See rank 11.
42	Otile et al. — AI in Surgical Healthcare Protocol (42843882)	⚪	3.05	3	5	2	2	3	7	Protocol	Protocol only; no findings.
43	Latif et al. — Laryngeal Amyloidosis Case Series (42843416)	⚪	3.55	4	2	5	3	2	7	Case series (n=2)	Extreme rarity; n=2; hypothesis-generating only.
44	Sabzevari Rad & Siahkouhian — Tabata + Cinnamon RCT (42841356)	⚪	2.45	2	2	3	3	3	7	RCT (n=14)	n=14 is critically underpowered; non-clinical population; narrow generalisability.
45	Kosmidis et al. — ML Causal Estimation in Nursing Research (42843401)	⚪	3.70	3	5	4	3	3	5	Scoping Review	Methodological contribution. Abstract only. Low clinical relevance.

Why it matters — Top Article:

Every AML patient starting venetoclax-based therapy who also needs antifungal protection can now be treated with both simultaneously and with greater confidence — this meta-analysis provides the strongest available evidence that their remission odds are not meaningfully compromised.

Deep dive 1 Reducing Inequalities in Bowel Cancer Screening PMID 42842613 ↗

[HOOK]

Bowel cancer is one of the most preventable and detectable cancers we have — when screening actually happens. But in the United Kingdom and many other countries, there's a persistent, stubborn gap: people living in deprived communities are significantly less likely to get screened, and they're far more likely to be diagnosed late, when treatment is harder and survival is shorter. This systematic review asks a deceptively simple question: what actually works to close that gap?

[THE DISCOVERY]

Researchers Meaden, Phillpotts, and Turner conducted a systematic review examining intervention strategies designed to improve bowel cancer screening uptake specifically in socioeconomically deprived communities. Their central finding is sobering and honest: while interventions exist and some show promise, the evidence base is still insufficient to clearly identify which strategies work best, why they work, and exactly when in the screening pathway they should be applied. The review identifies a need for better understanding of decision-making processes and the mechanisms that actually drive effectiveness in this population.

[THE SCIENCE BEHIND IT]

This is a systematic review — meaning the researchers pooled evidence from multiple studies rather than conducting a new trial of their own. Systematic reviews sit near the top of the evidence hierarchy because they synthesise the field's knowledge. The key limitation here is that the conclusion calls for more research, which tells us that the primary studies feeding this review were heterogeneous or inconclusive. This limits the review's immediate actionability. We do not have access to the full text, so specific effect sizes or the number of included studies are not available for independent verification.

[WHO THIS HELPS]

The populations most directly relevant are people in lower socioeconomic brackets in the UK and comparable high-income countries — those who receive a bowel cancer screening invitation but don't complete it. This includes individuals in areas of high deprivation who may face barriers such as health literacy challenges, distrust of healthcare institutions, logistical obstacles, or simply never receiving an invitation that feels relevant to their lives. These are the very people for whom early detection would make the biggest difference, because late-stage diagnosis is more common in deprived groups.

[THE REAL-WORLD IMPACT]

If the findings from this review and the future research it calls for are translated into national screening programme design, the downstream effects could be substantial. The UK NHS Bowel Cancer Screening Programme invites approximately 3.5 million people annually. Even a modest increase in uptake among the most deprived quintile — who currently show markedly lower participation — could shift diagnoses from Stage III/IV to Stage I/II, where 5-year survival jumps from below 15% to above 90%. The bottleneck right now is not the test itself; it's getting people to use it. That is fundamentally a behavioural and system design problem.

[WHAT WE STILL DON'T KNOW]

The review explicitly flags that the decision-making processes of people who decline screening are poorly understood. We don't know whether the most effective interventions are community-based outreach, GP-level nudges, simplified test delivery, culturally tailored materials, or financial incentives — or whether effectiveness varies by deprivation subtype (rural vs. urban, ethnic minority vs. white working class). Without that mechanistic understanding, programmes risk implementing generic solutions that don't move the needle.

[LIKELIHOOD OF MAKING A DIFFERENCE]

Scientific Confidence: Moderate — systematic review identifies a real problem but without a definitive intervention answer
Translation Speed: 2–5 years (if a high-quality follow-on programme trial is funded and completed)
Barrier Analysis:
- Infrastructure: NHS screening infrastructure exists; barriers are programme design, not technology
- Awareness: Both among patients and commissioners of evidence-based intervention options
- Equity: This is the core motivation — but without clearer evidence, well-meaning programmes may repeat low-impact approaches
- Reimbursement: Not a barrier at the programme level in the NHS; could be relevant in fragmented health systems

[CALL TO ACTION / CLOSING]

Catching bowel cancer early is genuinely life-saving — and the evidence tells us that the people most likely to be diagnosed late are precisely those we're least effectively reaching. We don't yet have a perfect playbook, but this review maps the gaps so the next generation of trials can fill them. The science of screening is only as good as the people it actually screens.